Lancet Neurology

Article	Citations
Diversity and inclusion in neurosurgery	4146
Score fluctuation might be associated with a higher placebo rate in the RAISE trial	917
The hidden unity of the mind	618
Treatment of asymptomatic carotid stenosis in SPACE-2	602
With thanks to our peer reviewers in 2022	587
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply	566
Correction to Lancet Neurol 2025; 24: 65–76	443
The reality of multiple sclerosis assessment in middle-income countries	428
Disparities in neurosurgical care for traumatic brain injury	395
Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial	372
Amyotrophic lateral sclerosis caused by hexanucleotide repeat expansions in C9orf72: from genetics to therapeutics	363
Healthy brain in a healthy body	358
From film to philanthropy	345
The challenge of pregnancy in women with multiple sclerosis	340
Crossing the blood–brain barrier: emerging therapeutic strategies for neurological disease	336
The African Dementia Consortium	328
Global burden of stroke: dynamic estimates to inform action	306
Women in Neurosurgery: breaking barriers	265
Extended-interval dosing of natalizumab in NOVA – Authors' reply	250
A neurological journey to save lives in Haiti	233
Medieval treatment of epilepsy in England	233
Lightning progress in child neurology in the past 20 years	230
Tanuja Chitnis: on role models, family, and multiple sclerosis	229
Spiralling towards an ending	227
Dancing with paper	217

Anatomy embroiders function in Purkinje cells	211
Malformations of cortical development as models of altered brain excitability	206
Maeike Zijlmans	194
Vittorio Marchi's staining	183
Effect of frailty on 6-month outcome after traumatic brain injury: a multicentre cohort study with external validation	183
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority tr	180
The wisdom of our mentors: clinical pearls in movement disorders	179
Pseudomedicine for sports concussions in the USA	175
Transforming amyotrophic lateral sclerosis into a liveable disease	170
Elevating the wellbeing of neurologists	167
Anticoagulation for patients with device-detected atrial fibrillation and a history of stroke	166
Licence to practise	162
CGRP-targeted drugs for migraine: still many uncertainties	158
Fetal exposure to antiseizure medications: reassurance and concerns	157
Elisaveta Sokolov	156
Journey down memory lane	148
Sex, gender, and the cost of neurological disorders	148
V Wee Yong: a journey of rediscovery	147
Giuseppe Citerio's neurocucina	141
Form and function in the brain	138
The social network of functional neurological disorder	137
Tatyana Shelkovnikova	137
COP27 Climate Change Conference: urgent action needed for Africa and the world	134
A new classification for diagnosis of optic neuritis	133
The evolving paradigm of Alzheimer's disease diagnosis	132
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease – Authors' reply	131
Application of diagnostic criteria for optic neuritis	130
Chronic effects of inflammation on tauopathies	126
Multiple sclerosis: two decades of progress	123
α-synuclein seed amplification in Parkinson‘s disease	121
Stroke advances in 2023: a new horizon for the management of intracerebral haemorrhage	119
Appropriate selection of participants for clinical trials in epilepsy	118
Forging ahead in haemorrhagic stroke research	113
A neurotransmitter with a fascinating story	113
What we remember	111
Association of Pick's disease with the MAPT H2 haplotype	110
PROMISE of low-cost immunosuppressants for myasthenia gravis	108
The predictive value and clinical use of the neurological pupillary index – Authors' reply	103
Monitoring patients with severe traumatic brain injury	102
Innovation in the prevention of neurological diseases	101
A contentious FDA ruling for Alzheimer's disease	100
Dementia care: beyond a diagnosis	99
Huntington's disease: disappointments and new beginnings	99
Climate change and neurology: time to talk and to act	96
Lessons and future directions for GBA1-targeting therapies	94
Intracranial pressure monitoring and unfavourable outcomes	93
Georgios Tsivgoulis: in top gear	93
20th Anniversary photography competition: neurology for zoomers	90
Headache in 2021: clinical, biological, and genetic advances	88
Leriglitazone: frustration and hope in adrenoleukodystrophy	88

Intra-arterial bone marrow mononuclear cells for stroke	86
A disease-specific therapy in facioscapulohumeral muscular dystrophy	85
The shortage of thrombolytics for stroke: a call for action	85
Traumatic brain injury advances since 2017: what has changed?	85
Ischaemic stroke in 2024: progress on multiple fronts	84
Reconsidering prourokinase for acute ischaemic stroke	83
Jules Froment's neurological statuettes	83
Correction to Lancet Neurol 2024; 23: 393–403	82
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial	82
Carotid artery overtreatment in the USA	79
Amyotrophic lateral sclerosis: a lesson in translation	79
Making brain health a global priority	78
WHO launches its Global Action Plan for brain health	77
Dementia diagnosis in the anti-amyloid era	76
Neurological disorders caused by novel non-coding repeat expansions: clinical features and differential diagnosis	76
Speculation on the transmissibility of Alzheimer's disease	75
The relevance of social and commercial determinants for neurological health	74
Tom Solomon: world records, academic leadership, and emerging infections	74
Dementia research in 2022: advancing steadily on reflection	73
Elinor Ben-Menachem: a talented risk-taker with great results	73
Angela Vincent: a pioneer of immune-mediated disease	71
Multidisciplinary care for amyotrophic lateral sclerosis	70
Addressing neurological burden in the Americas	69
Apomorphine infusion for improving sleep in Parkinson's disease	69
Cristina Tassorelli: making a difference in headache research	69
Health as a philosophical idea	69
Concerns with the new biological research criteria for synucleinopathy	69
Implications of the KIWE trial for low-income and lower-middle-income countries	69
γ-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational	68
CNS disease associated with enhanced type I interferon signalling	67
Considerations for future trials in cerebral cavernous malformations – Authors' reply	67
Amyloid removal and the appearance of brain volume loss	67
A biobank for Parkinson's disease and atypical parkinsonism in central Asian and Transcaucasian regions	67
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial	65
New therapies for Pompe disease: are we closer to a cure?	65
Could SARS-CoV-2 cause tauopathy?	65
The East Asian Parkinson Disease Genomics Consortium	65
Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study	64
Seizure prevention in patients with intracerebral haemorrhage	64
Cerebral amyloid angiopathy criteria: the next generation	64
Access to investigational drugs for patients with amyotrophic lateral sclerosis in the USA	63
Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH): a randomised, double-blind, placebo-controlled, phase 3	62
Neuroscience highlights in 2022: cytoskeletal transport	60
The prognostic potential of pupillometry in patients with acute brain injury	60
Admission systolic blood pressure and effect of endovascular treatment in patients with ischaemic stroke: an individual patient data meta-analysis	60
Kerstin Hellwig: educating on multiple sclerosis and pregnancy	58
Treatment of acute subdural haematoma – Authors' reply	57
The EyeVu Consortium for global neurosurgery	57
Cardiovascular disease after traumatic brain injury: the heart of the matter	56
A spirited community that knows how to fight	56
Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, r	56
Azathioprine and mycophenolate mofetil in myasthenia gravis – Authors' reply	55
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease	55
Rare diseases: we need to think about climate change too	53
Anticoagulation in people with atrial fibrillation after intracranial haemorrhage	53
CSF factors in memory function	50
Treatment for Alzheimer's disease: time to get ready	49
Inspiring the next generation	48
The Brain Research Africa Initiative (BRAIN)	48
Time to end the stigma of epilepsy	47
Integrated approach to stroke burden: are we doing enough?	47
Effects of climate change on the brain: an environmental neurology perspective	47
Raising awareness of degenerative cervical myelopathy	47
Surgical treatment for chronic subdural haematoma	46
The elusive foundations of creativity	46
Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study	45
Post-mortem neuropathology of idiopathic rapid eye movement sleep behaviour disorder: a case series	45
Frank Longo: taking on Alzheimer's disease	45
Traumatic brain injury research: homogenising heterogeneity	44
Correction to Lancet Neurol 2021; 20: 762–72	44
Has the time come to redefine Parkinson's disease?	44
Increasing diversity in dementia research	44
Correction to Lancet Neurol 2022; 21: 42–52	43
Correction to Lancet Neurol 2024; 23: 168–77	43
RAB32 mutation in Parkinson's disease	42
Correction to Lancet Neurol 2021; 20: 1038–47	42
The Yaoundé Declaration	41
Differential diagnosis of suspected multiple sclerosis: considerations in people from minority ethnic and racial backgrounds in North America, northern Europe, and Australasia	41
Important considerations for children with non-dystrophic myotonia	41
Improving access to medicines for neurological disorders	41

Correction to Lancet Neurol 2023; 22: 1160–206	40
Correction to Lancet Neurology 2021; 19: 1033–42	40
Correction to Lancet Neurol 2021; 20: 448–59	39
Correction to Lancet Neurol 2021; 20: 703–04	39
Correction to Lancet Neurol 2022; published online Sept 29. https://doi.org/10.1016/ S1474-4422(22)00309-X	39
Nursing homes with a difference: the outdoors inside	38
Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study	37
Challenges of Parkinson's disease GWASs in African people	37
Differential diagnosis of suspected multiple sclerosis: global health considerations	37
Incremental prognostic value of acute serum biomarkers for functional outcome after traumatic brain injury (CENTER-TBI): an observational cohort study	36
Surgery versus conservative treatment for traumatic acute subdural haematoma: a prospective, multicentre, observational, comparative effectiveness study	35
The debate on how to protect and restore brain health	35
Long-term risk of cardiovascular disease after traumatic brain injury: screening and prevention	33
Genetic basis of lacunar stroke: a pooled analysis of individual patient data and genome-wide association studies	33
Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study	33
Strategic infarct locations for post-stroke cognitive impairment: a pooled analysis of individual patient data from 12 acute ischaemic stroke cohorts	33
The link between blood pressure and Alzheimer's disease	33
Mitochondrial disease in adults: recent advances and future promise	31
Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial	30
Management of atherosclerotic extracranial carotid artery stenosis	29
RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses	29
Sleep function: an evolutionary perspective	29
Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4·5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-in	28
Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in the Netherlands (PASSIoN): a first-in-human, open-label intervention study	28
Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial	28
Drug resistance in epilepsy	28
A biological classification of Huntington's disease: the Integrated Staging System	27
Autoimmune encephalitis: chasing a moving target	27
Anti-CD19 CAR T cells for refractory myasthenia gravis	27
Diagnosis and classification of optic neuritis	27
Neuromodulation in epilepsy: state-of-the-art approved therapies	26
Advances in Alzheimer's disease research over the past two decades	26
Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities	26
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study	26
Lecanemab slows Alzheimer's disease: hope and challenges	25
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research	24
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study	24
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial	24
Prehospital screening of acute stroke with the National Institutes of Health Stroke Scale (ParaNASPP): a stepped-wedge, cluster-randomised controlled trial	24
Moyamoya disease: diagnosis and interventions	23
Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study	23
Carpal tunnel syndrome: updated evidence and new questions	23
Progression of cerebral amyloid angiopathy: a pathophysiological framework	23
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group	23
The neuropsychiatry of Parkinson's disease: advances and challenges	23
Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 tri	23
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study	22
Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials	22
Multiple sclerosis progression: time for a new mechanism-driven framework	22
Considering the neurological health needs of LGBTQIA people	21
Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study	21
Walker's miracle of science	21
Highlights in traumatic brain injury research in 2023	21
Action needed on social and commercial determinants of neurological health – Authors' reply	21
Anticoagulants to prevent recurrent non-cardioembolic stroke	21
Rigmor Højland Jensen: the headache warrior	21
Credulity of exploratory trials for cerebral cavernous malformations	20
Sleep and sleep disorders in people with Parkinson's disease	19
WHO considers multiple sclerosis treatments essential	19
Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crosso	19
A multipronged approach to advancing palliative care for people with intellectual disabilities	19
Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial	19
Prevention of dementia with holistic brain health	19
Prioritising integration of palliative care to prevent suffering	18
Pierre Amarenco: the persistent pioneer	18
Trials in intracerebral haemorrhage: a path to success?	18
A chilly tale of dementia	18
Thank you to The Lancet Neurology's peer reviewers in 2022	18
Alzheimer's disease: a history revisited	18
Identifying the best biomarkers for α-synucleinopathies	17
Correction to Lancet Neurol 2019; 18: 329–31	17
Antibiotic neuromuscular junction myasthenic mimetics	17
Time to reconsider the classification of multiple sclerosis	17
Esme Ekizoglu Turgut	17
Karen Duff: blazing a path in dementia research	17
Improving prognostication after severe brain injury	16
Idiopathic hypersomnia: does first to approval mean first-line treatment?	16
20 years of hammers, pins, and hope	16
The promises and pitfalls of brain repair	16
Management of Alzheimer's disease takes a leap forward	16
A celebration of neurology in the 21st century	16
Safe laboratory management of prions and proteopathic seeds	16
Treating apathy in frontotemporal dementia	15
Mar Tintoré, Mar Mediterráneo	15
Genome sequencing for the fast diagnosis of early-onset epilepsies	15
Changing views of disability	15
Daridorexant for insomnia disorder	15
Italy's actions on dementia	15
Asymptomatic carotid stenosis and stroke risk – Authors' reply	15
Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study	15
Beyond the modular brain	14
A genetic basis for the severity of multiple sclerosis	14
Turin as a neuroscience cradle	14
Mesenchymal stem cells for multiple sclerosis: hype or hope?	14
Alison Christy	14